Breast Cancer

Clarient provides more than 350 diagnostic tests to assess and characterize tumors, including tests for BRAF, KRAS, and EGFR gene mutations.

Dr. Harold Harvey from Penn State Hershey Cancer Institute Discusses Preventing Breast Cancer

The options for exploring tumor biology continue to multiply amid technological advances that are making molecular testing options a routine part of oncology treatment.

Dr. Jose Baselga from Massachusetts General Hospital Discusses the BOLERO Breast Cancer Trials

Since the discovery of the HER2/neu gene in the late 1970s, aberrations in the HER2 signaling pathway have been implicated in a wide variety of human cancers.

Dennis Slamon, MD, PhD, and Carlos L. Arteaga, MD, discuss recent advances in anti-HER2 targeted therapies and the role of signaling by oncogenes.

Dr. Lawrence Solin from Einstein Medical Center on Personalizing Treatment With the DCIS Score

The Miami Breast Cancer Conference has become a well-respected and well-attended gathering that specialists make a point of returning to year after year.

Dr. Howard Burris from Sarah Cannon Research Institute Discusses Recurrence Scores Predicting pCR

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses Optimizing Adjuvant Therapy

Dr. Freya Schnabel from NYU School of Medicine on Predicting Breast Cancer by Atypia Type

Dr. Harold Harvey from Penn State Hershey Cancer Institute on Aromatase Inhibitor Treatment Duration

This commentary will highlight 2 phase III randomized trials and a retrospective review of a large national database that has been strongly criticized based on its overall conclusions.

New data show that roughly one-fifth of tamoxifen-treated male patients with breast cancer stop treatment early because of side effects.

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

The use of a navigation program for an urban safety net breast cancer population has only a moderate effect on the time from symptom presentation to treatment.

New data show that while men are diagnosed with breast cancer at a mere fraction of the rate of women, they tend to have more advanced disease at the time of diagnosis.

The combination of anastrozole and fulvestrant improved survival when used as first-line therapy in postmenopausal women with metastatic HR-positive breast cancer compared with anastrozole alone.

Patients with metastatic breast cancer who were treated with eribulin mesylate were less likely to experience peripheral neuropathy.

The developing theme is that bisphosphonates are most effective in postmenopausal patients with HR-positive breast cancer.

While pertuzumab is moving ahead in the FDA approval process, an additional indication for denosumab might be halted.

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Describes Retesting Recurrent Breast Cancer

Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial

Upfront zoledronic acid is superior to delayed use in postmenopausal women with early breast cancer who are being treated with the aromatase inhibitor letrozole.

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses Targeting the mTOR Pathway

Dr. Kevin Fox, from Abramson Cancer Center, Discusses Genomic Testing in Breast Cancer

Dr. Harold Burstein, from the Dana-Farber Cancer Institute, Discusses Pathological Complete Response

Dr. Linda Vahdat, from New York-Presbyterian Hospital, Discusses the Side Effects of Halaven

Two new studies suggest that dual inhibition of HER2 might serve as a better approach to treating patients with HER2-positive breast cancer.